The Berlin-based biotechnology company MOLOGEN AG announced today that the European Patent Office intends to grant the patent for DNA-vaccines against Leishmaniasis for use in humans and in companion animals. The vaccines contain different combinations of MIDGE-Th1 vectors. Each vector encodes a different target structure (antigen) of the pathogens causing the infection. One of these combinations of antigens is already contained in the MIDGE-based DNA vaccine against Leishmaniasis in companion animals. The vaccine is currently subject of an advanced clinical development program, which is conducted by an undisclosed world-wide leading animal health company.
